iifl-logo
  • testing
  • |

iifl-logo

Mankind Pharma Ltd Board Meeting

2,376.4
(0.84%)
Jun 10, 2025|12:00:00 AM

Mankind Pharma CORPORATE ACTIONS

30/06/2024calendar-icon
30/06/2025calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting21 May 20258 May 2025
Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2025 inter alia to consider and approve Pursuant to Regulation 29 and 50 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Wednesday May 21 2025 inter-alia to consider and approve the standalone and consolidated audited financial results of the Company for the quarter and financial year ended on March 31 2025. Further in continuation of our earlier letter dated March 26 2025 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Conduct for Prevention of Insider Trading the trading window for trading in the securities of the Company shall remain closed till May 23 2025 Outcome of Board Meeting (As Per BSE Announcement Dated on: 21/05/2025)
Board Meeting14 Apr 202514 Apr 2025
Outcome of Board Meeting held on April 14, 2025
Board Meeting23 Jan 202513 Jan 2025
Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2025 inter alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended on December 31 2024. Outcome of Board Meeting held today i.e. January 23, 2025. (As Per BSE Announcement dated on 23.01.2025)
Board Meeting8 Jan 20258 Jan 2025
Outcome of the Board Meeting held today i.e. January 8, 2025.
Board Meeting16 Dec 202416 Dec 2024
Outcome of the Board Meeting under Regulation 30 of the SEBI (LODR) Regulations, 2015
Board Meeting3 Dec 20243 Dec 2024
Outcome of Board Meeting held today i.e. December 3, 2024
Board Meeting5 Nov 202425 Oct 2024
Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2024 inter alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30 2024 Outcome of Board Meeting held today i.e. November 5, 2024 (As per BSE Announcement Dated on 05/11/2024)
Board Meeting30 Sep 202430 Sep 2024
Outcome of Fund Raising Committee Meeting held today i.e. September 30, 2024
Board Meeting20 Sep 202417 Sep 2024
Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/09/2024 inter alia to consider and approve the raising of funds by way of issue of non-convertible debentures commercial papers other debt securities or any other security or any combination thereof for an amount as may be decided by the Board. Outcome of Board Meeting held today i.e. September 20, 2024 Raising of funds and issuance of corporate guarantee (As Per BSE Announcement dated on 20.09.2024)
Board Meeting31 Jul 202418 Jul 2024
Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2024 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of Board of Directors of the Company will be held on Wednesday July 31 2024 inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended on June 30 2024. Further in continuation of our earlier letter dated June 26 2024 under subject Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Conduct for Prevention of Insider Trading the trading window for trading in the securities of the Company shall remain closed till August 2 2024. The above notice and details are also being uploaded on the website of the Company at www.mankindpharma.com. Outcome of Board Meeting- Financial Results for the quarter ended June 30, 2024. (As Per BSE Announcement dated on 31.07.2024)

Mankind Pharma: Related News

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

testing
  • testing
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

testing
  • testing
  • testing

ATTENTION INVESTOR

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.